70 results about "Intestinal colonization" patented technology

The invention relates to the field of microorganisms, and discloses an aspergillus cristatus strain and application thereof. The preservation number of the aspergillus cristatus provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.41727. The aspergillus cristatus provided by the invention can produce chymosin at high yield, has excellent curding activity and relatively low proteolytic activity, and can reduce the bitter taste of dairy products and improve the yield; the aspergillus cristatus provided by the invention not only can shorten the fermentation time of the dairy product, improve the cream flavor of the dairy product, reduce the peculiar smell of the dairy product, balance the sourness and sweetness of the dairy product and improve the cinnamon flavor, but also has intestinal colonization ability, and has the potential of improving the flavor level of the dairy product and becoming intestinal probiotics.

The invention discloses a functional probiotic composition and application thereof, and relates to the technical field of microbial engineering. Bifidobacterium longum, lactobacillus acidophilus and enterococcus faecalis are combined to serve as a microbial agent, the microbial agent and active substances of the tea leaves form a composition, then the composition is combined with prebiotics, it is ensured that viable bacteria directly reach the intestinal tract through a microencapsulation technology, and the effect of improving the immune function is achieved; tea polyphenol in the active substances of the tea leaves can serve as a carbon source of prebiotics to stimulate proliferation of the bifidobacterium longum and the lactobacillus acidophilus, so that the acid resistance and intestinal colonization capacity of the microbial inoculum are enhanced, and meanwhile, theanine in the active substances of the tea leaves, the bifidobacterium longum and the lactobacillus acidophilus synergistically promote secretion of gamma-aminobutyric acid, so that the effect of improving the intestinal colonization is achieved. And the tea polyphenol can inhibit the large intestine rod from adhering to the intestinal mucosa, and the probiotic agent secretes antibacterial peptide, so that the integrity of the intestinal barrier is maintained together.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The present invention relates to the field of microbial technology, and specifically discloses a thermotolerant Propionibacterium freudenreichii subsp. shermanii strain PF37 and its application in intestinal colonization and symbiosis. The thermotolerant Propionibacterium freudenreichii subsp. shermanii strain PF37 was deposited with the China General Microbiological Culture Collection Center on March 21, 2025, and its deposit number is CGMCC No. 46389. This strain still has the ability of proliferation activity, fermenting and producing short-chain fatty acids, and promoting the colonization and proliferation of Bifidobacterium in the intestine at 34-37°C.

The invention belongs to the technical field of probiotics, and particularly relates to probiotics for improving intestinal health and application thereof. Wherein the probiotics for improving the intestinal health are a Lactobacillus plantarum LV1000 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.30865, and the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on June 5, 2024; through unique activation culture, streak separation and bacterial colony identification steps, high activity and high purity of the strain are ensured; based on the application of the strain, two product forms of probiotic microcapsules and probiotic compositions are developed, the probiotic microcapsules adopt sodium alginate, calcium lactate and other raw materials, the intestinal colonization ability of the strain is effectively improved, and the synergistic interaction of oxidation resistance and immunoregulation is achieved by combining rosa roxburghii tratt freeze-dried powder; and the probiotic composition can comprehensively regulate the balance of intestinal flora and improve the digestive function and intestinal motility.

The invention provides a bacillus subtilis strain and application thereof, the bacillus subtilis strain is named as bacillus subtilis Ya3.1, is preserved in China General Microbiological Culture Collection Center on July 7, 2025, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35019; the bacillus subtilis Ya3.1 is separated from intestinal tracts of healthy hybrid sturgeons, and can be used as a probiotic additive for aquaculture, especially for sturgeon culture. The bacillus subtilis Ya3.1 provided by the invention has high safety, strong stress resistance and efficient intestinal colonization ability, and can significantly improve the activity of sturgeon intestinal digestive enzymes, improve the growth performance of sturgeons, enhance the non-specific immunity of sturgeons, improve the intestinal flora structure and significantly improve the ability to resist aeromonas bacterial infection; and a special probiotic resource can be provided for sturgeon culture.

The invention discloses a composition containing probiotics and fusion polypeptide and application of the composition in treatment of intestinal inflammatory diseases. The composition is prepared from lactobacillus plantarum (Lactobacillus plantarum CCFM8661) and a functional fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the composition. The fusion polypeptide can be used for directly inhibiting the growth of pathogenic bacteria and neutralizing toxins by enhancing the intestinal colonization capability of probiotics, so that the triple synergistic effect of bacteriostasis, repair and immunoregulation is realized. Experiments show that the composition significantly reduces the disease activity index in a DSS-induced mouse colitis model, recovers the colon length, and inhibits serum inflammatory factors IL-6 and TNF-alpha. In addition, the survival rate of the freeze-dried microcapsule preparation in simulated gastric juice is gt; the colon targeted release characteristic is realized. The invention provides an efficient and stable new treatment strategy for intestinal inflammatory diseases.

The present invention discloses a CBP lysine children growth milk powder and a preparation method thereof, and belongs to the technical field of milk powder, the CBP lysine children growth milk powder comprises the following components by mass: a wet process part: 575 parts of whole milk powder, 175 parts of dried skim milk, 175 parts of isomaltooligosacharide (type 50) powder, 30 parts of polydextrose, 28 parts of edible plant blend oil, 4 parts of milk mineral salt, and 13.7 parts of a compound children modified milk powder three-nutrition enhancer; cBP lysine is cooperated with bifidobacterium and seven traditional Chinese medicine extracts, DHA and ARA are accurately proportioned, the calcium absorption efficiency and the intestinal colonization capacity of probiotics are remarkably improved, a three-step mixing method is combined with a two-way shearing low-temperature technology, rapid and uniform mixing is achieved, the activity of the probiotics and the stability of DHA are reserved to the maximum extent, high uniformity of products is ensured, and the product quality is improved. The low-moisture wet-process base powder inhibits moisture absorption of traditional Chinese medicine components, nitrogen protection blocks oxidation in the whole process, the shelf life is prolonged, and the reconstituability is improved.

According to the application disclosed by the invention, the new lactobacillus rhamnosus LR159 is found for the first time, and the strain can be used for effectively treating the inflammatory bowel disease by inhibiting the inflammation level, recovering the barrier function of intestinal mucosa and regulating and improving the intestinal microenvironment. Compared with known lactobacillus rhamnosus, the LR159 strain provided by the invention has better intestinal colonization ability, and can realize more lasting anti-inflammatory and mucous membrane repair effects by breaking through the limitation of pathological microenvironment of the inflammatory bowel disease, thereby enhancing the treatment effect of the inflammatory bowel disease. In conclusion, the lactobacillus rhamnosus LR159 has a great application prospect in preventing and treating the inflammatory bowel disease.

The invention belongs to the technical field of biology, and particularly discloses a pH response type probiotic-liposome hybrid system, a preparation method and application thereof, and the pH response type probiotic-liposome hybrid system comprises engineered escherichia coli Nissle 1917, pinocembrin-loaded biotinylated liposome and an enteric polymer; wherein the engineered escherichia coli Nissle 1917 is in non-covalent binding with the biotinylated liposome loaded with the pinocembrin through surface display streptavidin, so that EcNPIN is formed, and the EcNPIN is coated with an enteric polymer, so that the pH response type probiotic-liposome hybrid system is formed. The pH response type probiotic-liposome hybrid system EcNPIN-L provided by the invention can resist the acidic environment of the stomach, completes pH response release and colonization in the intestinal tract, solves the problems of lack of intestinal tract localization of drugs and low probiotic treatment efficiency, improves the local intestinal tract concentration of pinocembrin, and promotes intestinal tract colonization of probiotics.

The invention relates to the technical field of probiotic preparations, in particular to a process for preparing intestinal conditioning prebiotics from clostridium butyricum and radix astragali seu hedysari, which comprises the following steps: (1) multi-stage synergistic activation of clostridium butyricum; (2) carrying out composite enzymolysis on the astragalus extract; (3) symbiotic fermentation; (4) performing multi-layer embedding; the prepared prebiotics have a multi-dimensional intestine regulating mechanism, the bacteriostasis and mucous membrane repairing functions of the clostridium butyricum cooperate with the prebiotics effect and antioxidant activity of the astragalus polysaccharide to form a multi-protection system, and the intestinal flora imbalance is more effectively improved compared with single probiotics or prebiotics. The multi-layer embedding technology solves the problems of gastric acid inactivation and difficulty in intestinal colonization of probiotics, and spore induction of three-stage fermentation is matched, so that the viable count maintenance rate of the product is kept at a relatively high level after the product is stored for 6 months at normal temperature, and the shelf life is remarkably prolonged.

The invention discloses klebsiella pneumoniae and application thereof in production of indole-3-carboxylic acid (I3CA), and belongs to the fields of microbial technology, biological catalysis and fermentation engineering. The preservation number of the klebsiella pneumoniae is CCTCC NO: M 20252762, the classification name of the klebsiella pneumoniae is Klebsiella pneumoniae I3CA-02, the strain can efficiently convert tryptophan into I3CA in a time-dependent mode through a one-step method, high sensitivity to various clinically common antibiotics is kept, and the klebsiella pneumoniae has good intestinal colonization ability and safety, and can be used for preparing I3CA. The method has the potential of being directly applied to oral micro-ecological preparations and industrial production. The technical bottlenecks that the existing I3CA biosynthesis efficiency is low and the safety of recombinant bacteria is limited are broken through, the microorganism sources of indole derivatives are widened, and a foundation is laid for green manufacturing of high-purity I3CA and development of intestinal-brain-immune axis related functional products.

The invention relates to a microbial single-cell gelation encapsulation method based on aloe gel and application, the method realizes single-cell gelation encapsulation through electrostatic interaction of sterile aloe gel and intestinal anaerobic bacteria (such as Agathobacter rectasis), and the method comprises the specific steps of aloe gel preparation, bacterial suspension culture and oscillation mixing to form a stable structure. The preparation method has the advantages that the acid resistance and biocompatibility of the natural aloe gel are utilized to replace a traditional synthetic material, so that the gastrointestinal tolerance of thalli is improved; meanwhile, the synergistic effect of aloe active ingredients (such as aloe-emodin) and intestinal bacterial metabolites (butyric acid) is combined, so that the anti-inflammatory and intestinal steady-state regulation and control effects are enhanced. Experiments show that the survival rate of the encapsulated bacteria in simulated gastric juice within 4 hours is larger than or equal to 90%, the intestinal colonization rate is effectively increased compared with naked bacteria, the inflammatory factor level of a colitis model mouse can be remarkably reduced, and a safe and efficient new strategy is provided for micro-ecological treatment of inflammatory bowel diseases.

The invention discloses a probiotic strain Bifidobacterium animalis subsp. Lactiss S8 of a high-yield biological membrane, the preservation number is GDMCC NO.66518, the characteristics of the stable high-yield biological membrane are obtained through directional screening and adaptive evolution, and the yield of the biological membrane is three times higher than that of a positive control. The extracellular polymeric substance (EPS) of the strain can significantly enhance the tolerance of the strain to severe environments such as gastric acid, cholate and the like, and improve the intestinal colonization ability. Experiments prove that the strain remarkably reduces two liver function indexes, namely ALT and AST, in an animal model, and shows that the strain has a certain effect of improving liver injury.

The invention discloses a saccharomyces boulardii colon delivery system which comprises the following steps: the survival rate in gastric juice is enhanced, and the residence time in the colon is increased, so that the treatment effect of the saccharomyces boulardii is enhanced. Saccharomyces boulardii is taken as a research object, in order to improve the bioavailability of the Saccharomyces boulardii in gastrointestinal tracts and prolong the adhesion time of bacteria in intestinal tracts, a layer-by-layer electrostatic self-assembly method is adopted, PDAD (poly dimethyl diallyl ammonium chloride), PSS (sodium polystyrene sulfonate), CS (chitosan) and SA (sodium alginate) are taken as biological membranes to coat the Saccharomyces boulardii, and the coated Saccharomyces boulardii is prepared. Then a series of characterization is carried out, and the effect of the delivery system is verified through in-vitro artificial gastric juice tolerance tests and mouse intestinal colonization.

The invention discloses application of lactobacillus plantarum LP-Y01 and a fungicide thereof in preparation of a medicine for preventing and / or treating carbapenem-resistant drug-resistant bacterium infection. The invention verifies that the lactobacillus plantarum can generate a direct inhibition effect on carbapenem-resistant klebsiella pneumonia in vitro and has certain effective activity on colonization of the carbapenem-resistant klebsiella pneumonia in vivo through flora regulation and control. Probiotic pretreatment shows remarkable clinical potential by regulating and controlling a flora structure, provides a precise strategy for prevention and control of drug-resistant bacteria, and has a relatively good application prospect.

The invention relates to the technical field of nano engineering and probiotics, in particular to a bacteriostatic composition and a fungicide, a veterinary drug and a feed containing the bacteriostatic composition. The invention provides a bacteriostatic composition prepared by simultaneously mixing nano iron sulfide and lactobacillus, which can protect the intestinal colonization ability of lactobacillus and other beneficial bacteria, so that the nano iron sulfide promotes bacterial ferroptosis of pathogenic bacteria in the intestinal tract. The nano iron sulfide and the lactobacillus synergistically inhibit the growth of pathogenic bacteria such as escherichia coli, salmonella typhimurium and staphylococcus aureus in vitro and in intestinal tracts, have no adverse effect on beneficial bacteria and host intestinal epithelial cells, and are beneficial to intestinal health. The invention provides a natural and efficient application mode, and has very high conversion value.

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.

The invention discloses traditional Chinese medicine substitutional tea granules for aiding digestion and reducing fat and a preparation method thereof, probiotic microcapsules, traditional Chinese medicine lipid nanoparticles and Tibetan tea active ingredients are combined, and the effects of improving digestion and reducing fat are achieved through a triple synergistic mechanism. The probiotic microcapsules are embedded with citrus fibers through the poria cocos extract and then are mixed with the Chinese yam thick soup for freeze-drying, so that the survival rate of probiotics and the intestinal colonization effect are remarkably improved. The rhizoma alismatis and semen cassiae extracts are encapsulated in lecithin / lauric acid / palmitic acid lipid nanoparticles, so that unpleasant odor is covered, slow release is realized, and the metabolic regulation effects of palmitic acid and lauric acid are coordinated. In addition, Tibetan tea is used as a compound substrate, traditional Chinese medicines such as codonopsis pilosula, hawthorn and poria cocos are fused, honey, coix seeds and Chinese yam are used as auxiliary materials for granulation, and medicinal material natural polysaccharide is used for replacing a chemical adhesive. The product has probiotic activity protection, traditional Chinese medicine slow release and tea fragrance palatability, and has remarkable synergistic advantages in the aspects of improving the digestion function and regulating body fat.

The invention relates to the technical field of dairy products, in particular to a fermented dairy product based on compound ingredient flavor and nutrient enrichment and a preparation method of the fermented dairy product. The raw materials comprise 80-90 parts of raw milk, 3-8 parts of a composite flavor nutrition synergistic ingredient, 2-5 parts of a targeted release type nutrition enhancer, 0.3-1.0 part of a composite probiotic leavening agent, 0.1-0.8 part of a gamma-ray modified functional stabilizer, 0.05-0.2 part of a microencapsulated natural antioxidant, 0.03-0.1 part of an intestinal colonization accelerant and the balance of deionized water. The fermented dairy product disclosed by the invention has the advantages of synergistic flavor and nutrition, high nutrition absorption and utilization rate, strong probiotic colonization capability, good product stability and long shelf life, has both high-quality sensory experience and comprehensive probiotic efficacy, and is superior to the existing fermented dairy product.

The invention discloses screening and application of a drug for inhibiting organ displacement of multi-drug-resistant klebsiella pneumoniae colonized in intestinal tracts. The invention provides any one of the following applications of a substance for inhibiting polarization of macrophages to M2: preparation of a product for treating diseases caused by multi-drug-resistant klebsiella pneumoniae infection; products for treating diseases caused by organ displacement of the multi-drug-resistant klebsiella pneumoniae are prepared; products for treating diseases caused by intestinal colonization of the multi-drug-resistant klebsiella pneumoniae are prepared; preparing a product for inhibiting organ displacement of the multi-drug-resistant klebsiella pneumoniae; preparing a product for inhibiting intestinal colonization of the multi-drug-resistant klebsiella pneumoniae; and a product for reducing or eliminating the number of bacteria in cells or organisms infected with multi-drug-resistant klebsiella pneumoniae is prepared. By inhibiting polarization of macrophages to M2, organ infection and intestinal colonization of multi-drug-resistant klebsiella pneumoniae are effectively inhibited.

The invention belongs to the technical field of prebiotics, and particularly relates to plant extract composite prebiotics as well as a preparation method and application thereof. The invention provides a plant extract composite prebiotics, which is prepared by compounding a purslane ethanol extract and a common turnip ethanol extract in equal mass ratio, and the purslane ethanol extract and the common turnip ethanol extract are prepared by soaking purslane and common turnip in an ethanol solution with the volume concentration of 94-96%, performing ultrasonic extraction, concentrating and freeze-drying. The plant extract composite prebiotics provided by the invention can remarkably promote the growth of probiotics such as lactobacillus plantarum, lactobacillus paracasei and pediococcus pentosaceus, have the effects of regulating intestinal flora balance and promoting intestinal colonization of the probiotics, and also have antioxidant activity, thereby providing a new choice for development of prebiotics with natural sources.

The invention provides feline-derived lactobacillus delbrueckii, a metagen, a pharmaceutical composition and application, the feline-derived lactobacillus delbrueckii is named as lactobacillus delbrueckii GYJC-003, the strain is preserved in the China Center for Type Culture Collection on September 2, 2024, and the preservation number is CCTCC NO: M 20241889. The feline-derived lactobacillus delbrueckii is named lactobacillus delbrueckii GYJC-003, and the feline-derived lactobacillus delbrueckii GYJC-003 is named lactobacillus delbrueckii GYJC-003. The lactobacillus delbrueckii GYJC-003 disclosed by the invention has the characteristics of being high in acid resistance and cholate resistance, strong in intestinal tract colonization ability, relatively good in probiotic effect and free from toxic and side effects, and a certain theoretical basis is provided for the development of the lactobacillus delbrueckii GYJC-003. The lactobacillus delbrueckii GYJC-003 disclosed by the invention has the advantages that the lactobacillus delbrueckii GYJC-003 disclosed by the invention can be used for preparing the lactobacillus delbrueckii GYJC-003;

The invention relates to application of plant lactobacillus FBL002 in bird's nest fermentation, and belongs to the technical field of fermentation. The invention finds that the plant lactobacillus FBL002 has stable intestinal colonization ability and antioxidant activity, and can significantly improve the antioxidant ability of an aged mouse and relieve an inflammatory state in an aged mouse model. When the plant lactobacillus FBL002 is applied to bird's nest fermentation, bird's nest protein can be decomposed into small molecule active peptides (the total peptide content is larger than or equal to 12%), 90% of sialic acid can be reserved, and meanwhile, synergistic antioxidant components such as short-chain fatty acid, SOD (the SOD activity is larger than or equal to 150 U / g) and vitamin B can be generated; therefore, the cubilose fermentation liquor prepared by the fermentation method disclosed by the invention has high oxidation resistance (the ABTS free radical scavenging rate is greater than 90%) while retaining 90% of cubilose acid, and has a wide application prospect.

This invention relates to the technical field of food processing, specifically to a method for preparing and applying probiotics that can improve intestinal colonization efficiency. The method uses corydalis yanhusuo protein as one of the reaction substrates and employs a two-stage fermentation process to cultivate probiotics. In the first stage of fermentation, the probiotics rapidly proliferate and produce spores. In the second stage of fermentation, they form a biofilm. The resulting probiotic fermentation broth is then dried and pulverized to produce the probiotic powder that improves intestinal colonization efficiency. This invention's preparation method is the first to employ a high-density fermentation mode that enhances the formation of a probiotic biofilm. By adjusting the initial fermentation medium ratio and fermentation parameters, the probiotics rapidly proliferate and produce spores. In the second stage of fermentation, the medium is supplemented and parameters are changed to achieve biofilm formation. This method solves the technical difficulties of slow proliferation and low biomass in single-stage biofilm static culture of probiotics, as well as the problems of poor processing tolerance and intestinal membrane adhesion of planktonic probiotics.

The invention discloses bifidobacterium breve HX-5M3 and application thereof, and belongs to the technical field of biomedicine. The bifidobacterium breve HX-5M3 disclosed by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the bifidobacterium breve HX-5M3 is CCTCC (China Center for Type Culture Collection), and the preservation number of the bifidobacterium breve HX-5M3 is CCTCC NO: M 20242244. The invention also discloses an application of the bifidobacterium breve HX-5M3 in preparation of a product for metabolizing oligosaccharide in breast milk. The strain HX-5M3 disclosed by the invention not only can efficiently utilize LNT and LNnT, but also shows good metabolic capability on 2 '-FL and 3-FL; the strain can tolerate cholate, has good intestinal colonization potential, is sensitive to various antibiotics, and does not produce hemolysin. The strain HX-5M3 disclosed by the invention has a large number of GHs genes related to HMOs metabolism, which indicates that the strain HX-5M3 has a relatively strong utilization capability on decomposing carbohydrates, especially on HMOs.

The invention discloses a polyphenol-calcium phosphate-hyaluronic acid multifunctional probiotic delivery carrier with an adjustable structure and a preparation method of the polyphenol-calcium phosphate-hyaluronic acid multifunctional probiotic delivery carrier. The carrier is constructed by regulating calcium phosphate mineralization through polyphenol to form a flower-like structure and then adsorbing hyaluronic acid. The preparation method comprises the following steps: (1) preparing nanoflowers from polyphenol chelated calcium phosphate; (2) in-situ packaging of probiotics by the nanoflowers; and (3) coating the probiotic carrier with hyaluronic acid. The preparation method is simple in process and mild in condition, the prepared probiotic packaging body is excellent in biocompatibility, not only can improve gastrointestinal fluid environment tolerance, but also has the capabilities of active oxygen removal, inflammation targeting and intestinal colonization, and by synergistically reducing colitis, relieving tissue damage, repairing intestinal mucosal barrier and restoring intestinal flora balance, the intestinal tract intestinal colonization effect is improved. A new strategy is provided for the treatment of the inflammatory bowel disease.

This invention discloses a composition comprising probiotics and a fusion polypeptide and its application in the treatment of inflammatory bowel diseases. The composition consists of *Lactobacillus plantarum* CCFM8661 and a functional fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide is shown in SEQ ID NO.1. This fusion polypeptide achieves a triple synergistic effect of "antibacterial inhibition-repair-immunomodulation" by enhancing the intestinal colonization ability of probiotics, directly inhibiting the growth of pathogenic bacteria, and neutralizing toxins. Experiments show that the composition significantly reduces the disease activity index, restores colon length, and inhibits serum inflammatory factors IL-6 and TNF-α in a DSS-induced mouse colitis model. Furthermore, the lyophilized microcapsule formulation exhibits a survival rate of >90% in simulated gastric juice and possesses colon-targeted release characteristics. This invention provides a highly efficient and stable new treatment strategy for inflammatory bowel diseases.

The invention discloses bifidobacterium longum subsp. Infantis HX-4M1 and application thereof, and belongs to the technical field of biomedicine. The bifidobacterium longum subsp. Infantis HX-4M1 disclosed by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the bifidobacterium longum subsp. Infantis HX-4M1 is CCTCC (China Center for Type Culture Collection) NO: M 20242243. The invention also discloses an application of the bifidobacterium longum subsp. Infantis HX-4M1 in preparation of a product for metabolizing oligosaccharide in breast milk. The strain HX-4M1 not only can efficiently utilize LNT and LNnT, but also shows good metabolic capability to 2 '-FL and 3-FL, can tolerate cholate, has good intestinal colonization potential, is sensitive to various antibiotics and does not generate hemolysin, has a large number of GHs genes related to HMOs metabolism of the strain HX-4M1, and contains typical HMOs metabolism gene clusters of model strains.

The invention discloses a screening and fermentation preparation method of high-yield antibacterial peptide probiotics, and relates to the technical field of microbial fermentation and animal nutrition, the method comprises three core steps of intestinal colonization-oriented multi-phenotype collaborative screening, self-assembled antibacterial peptide engineering bacterium construction, and in-situ nanocrystallization fermentation preparation. The preparation method comprises the following steps: firstly, screening out a probiotic host with gastrointestinal tolerance, colonization capability and self-assembly precursor peptide secretion potential, then constructing a fusion gene engineering bacterium containing an intestinal environment induced promoter, and finally, performing staged fermentation to realize fusion peptide in-situ self-assembly and spray drying to obtain a finished product, and the finished product contains colonization type recombinant viable bacteria and antibacterial peptide nanoparticles. The method can realize targeted colonization and long-acting bacteriostasis of intestinal tracts, has application stability and efficacy persistence, and is suitable for production of feed antibacterial peptide preparations.